Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2024-04-11 6-K RESULT OF AGM View Document
2024-04-11 6-K ASTRAZENECA INCREASES 2024 DIVIDEND BY 7% View Document
2024-04-08 6-K ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS View Document
2024-04-05 6-K IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC View Document
2024-04-02 6-K TOTAL VOTING RIGHTS View Document
2024-04-02 6-K VOYDEYA APPROVED IN US View Document
2024-04-02 6-K FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER View Document
2024-03-25 6-K ULTOMIRIS APPROVED IN THE US FOR NMOSD View Document
2024-03-19 DFAN14A DFAN14A View Document
2024-03-19 F-3ASR F-3ASR View Document
2024-03-19 6-K FORM 6-K View Document
2024-03-14 6-K ASTRAZENECA TO ACQUIRE AMOLYT View Document
2024-03-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2024-03-07 6-K FORM 6-K View Document
2024-03-07 6-K NOTICE OF AGM View Document
2024-03-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2024-03-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2024-03-06 CERT View Document
2024-03-05 8-A12B 8-A12B View Document
2024-03-04 6-K EMA VALIDATES DATO-DXD MAAS FOR NSQ NSCLC AND BC View Document
2024-03-01 6-K TOTAL VOTING RIGHTS View Document
2024-02-26 6-K FORM 6-K View Document
2024-02-26 6-K VOYDEYA RECOMMENDED FOR EU APPROVAL View Document
2024-02-23 424B2 424B2 View Document
2024-02-22 6-K ASTRAZENECA PRICES A $5BN BOND OFFERING View Document
2024-02-22 6-K FORM 6-K View Document
2024-02-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2024-02-22 FWP FWP View Document
2024-02-21 SC TO-T/A SC TO-T/A View Document
2024-02-21 424B2 424B2 View Document
2024-02-21 6-K FILING OF FORM 20-F WITH SEC View Document
2024-02-20 S-8 FORM S-8 View Document
2024-02-20 IRANNOTICE IRANNOTICE View Document
2024-02-20 20-F FORM 20-F View Document
2024-02-20 6-K FORM 6-K View Document
2024-02-20 6-K ANNUAL FINANCIAL REPORT View Document
2024-02-20 SC TO-T/A SC TO-T/A View Document
2024-02-20 6-K FORM 6-K View Document
2024-02-20 6-K ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX View Document
2024-02-20 6-K TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER View Document
2024-02-20 6-K FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC View Document
2024-02-20 6-K TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER View Document
2024-02-15 SC TO-T/A SC TO-T/A View Document
2024-02-12 SC 13G/A SC 13G/A View Document
2024-02-08 6-K FINAL RESULTS View Document
2024-02-01 6-K TOTAL VOTING RIGHTS View Document
2024-01-24 SC 13G/A View Document
2024-01-19 SC TO-T/A SC TO-T/A View Document
2024-01-19 6-K FORM 6-K View Document
2024-01-11 SC TO-T/A SC TO-T/A View Document
2024-01-10 CORRESP View Document
2024-01-02 6-K TOTAL VOTING RIGHTS View Document
2023-12-27 SC TO-T SC TO-T View Document
2023-12-27 6-K ASTRAZENECA ACQUIRES GRACELL View Document
2023-12-26 6-K FORM 6-K View Document
2023-12-22 6-K WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL View Document
2023-12-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-12-12 SC TO-C SC TO-C View Document
2023-12-12 6-K FORM 6-K View Document
2023-12-12 6-K ASTRAZENECA TO ACQUIRE ICOSAVAX View Document
2023-12-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2023-12-01 6-K TOTAL VOTING RIGHTS View Document
2023-12-01 6-K DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS View Document
2023-11-24 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-11-17 6-K TRUQAP APPROVED IN US FOR HR+ BREAST CANCER View Document
2023-11-16 SC 13D/A SC 13D/A View Document
2023-11-14 25-NSE View Document
2023-11-14 6-K UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI View Document
2023-11-13 144 View Document
2023-11-09 SC 13D SC 13D View Document
2023-11-09 6-K DIRECTOR DECLARATION View Document
2023-11-09 6-K IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER View Document
2023-11-09 6-K AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA View Document
2023-11-09 6-K 9M AND Q3 2023 RESULTS View Document
2023-11-01 6-K TOTAL VOTING RIGHTS View Document
2023-11-01 6-K ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS View Document
2023-10-03 6-K ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS View Document
2023-10-02 6-K TOTAL VOTING RIGHTS View Document
2023-09-25 6-K DATO-DXD IMPROVED PFS IN BREAST CANCER View Document
2023-09-20 6-K ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT View Document
2023-09-15 6-K ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC View Document
2023-09-11 6-K FASENRA PHASE III EGPA TRIAL MET PRIMARY ENDPOINT View Document
2023-09-06 6-K UPDATE ON US REVIEW OF ULTOMIRIS FOR NMOSD View Document
2023-09-01 6-K TOTAL VOTING RIGHTS View Document
2023-08-16 25-NSE View Document
2023-08-01 6-K TOTAL VOTING RIGHTS View Document
2023-07-28 6-K FORM 6K View Document
2023-07-28 6-K ALEXION ENTERS GENE THERAPY AGREEMENT WITH PFIZER View Document
2023-07-17 6-K BEYFORTUS APPROVED IN US FOR INFANT RSV PREVENTION View Document
2023-07-03 6-K TOTAL VOTING RIGHTS View Document
2023-07-03 6-K DATO-DXD SIGNIFICANTLY IMPROVED PFS IN LUNG CANCER View Document
2023-06-28 11-K ANNUAL REPORT View Document
2023-06-09 6-K NIRSEVIMAB RECOMMENDED FOR INFANT RSV PROTECTION View Document
2023-06-09 6-K ASTRAZENECA AGREEMENT WITH QUELL THERAPEUTICS View Document
2023-06-02 6-K IMFINZI IMPROVED PCR IN GASTRIC AND GEJ CANCERS View Document
2023-06-01 6-K BLOCK LISTING INTERIM REVIEW View Document
2023-06-01 6-K TOTAL VOTING RIGHTS View Document
2023-06-01 6-K LYNPARZA APPROVED IN US FOR BRCAM PROSTATE CANCER View Document
2023-05-26 6-K IMFINZI + LYNPARZA PROLONGED PFS IN ENDOMETRIAL CANCER View Document
2023-05-25 25-NSE View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299